Grants and Contracts Awarded to Yale School of Medicine

May/June 2006


  • Morris Bell, NIH, Cognitive Training and Enhanced Supported Employment, 5 years, $2,138,756
  • Christopher Breuer, NIH, Development of Second-Generation Tissue-Engineered Vascular Grafts, 5 years, $673,650
  • Tania Burgert, NIH, Postprandial Glycemia in Association with Vascular Disease in Childhood Obesity, 3 years, $384,544
  • Elizabeth Claus, NIH, Meningioma: Risk Factors and Quality of Life, 5 years, $3,383,676
  • Mark Cullen, NIH, Disease, Disability and Death in an Aging Workforce, 5 years, $5,236,618
  • Pietro De Camilli, NIH, Molecular Mechanisms in Synaptic Vesicle Recycling, 4 years, $1,177,200
  • Robin de Graaf, NIH, Novel Technologies for Global Optimization of Magnetic Field Homogeneity, 2 years, $332,273
  • Enrique De La Cruz, NSF, Kinetic Mechanism of DEAD-box RNA Helicase ATPase, 5 years, $942,639
  • Donald Engelman, NIH, TM Interactions in Membrane Protein Folding and Function, 4 years, $1,754,952
  • Durland Fish, NIH, Spread of Lyme Borreliosis Bacteria in the U.S., 2 years, $449,625
  • Sankar Ghosh, NIH, Regulation and NF-κB and IκB Proteins, 5 years, $2,065,833
  • Erol Gulcicek, NIH, Differential Gel Electrophoresis (DIGE) System for Yale University Keck Laboratory, 1 year, $405,284
  • Joan Kaufman, NIH, Genetic and Environment Modifiers of Child Depression, 5 years, $1,858,595
  • Brian Leaderer, NIH, Asthma Severity in Children and Fine Particle Composition, 5 years, $2,819,762
  • Elias Lolis, NIH, Functional and Structural Studies of CD74 Activation, 5 years, $2,065,833
  • Xingguang Luo, NIH, Fine-Mapping the Risk Loci for Alcoholism in ADH Gene Cluster and ALDH2 Gene, 5 years, $732,816
  • Robert Malison, NIH, Drug Abuse, Sleep and Cognition, 3 years, $975,109
  • Ruslan Medzhitov, NIH, Cell Biology of TLR Signal Transduction, 5 years, $1,839,375
  • Gero Miesenboeck, Office of Naval Research, Computation in Neuronal Microcircuits, 1 year, $400,000
  • Michael Nathanson, NIH, Regulation of Liver by Nuclear Ca2+ Signaling, 5 years, $5,954,074
  • Jullie Pan, NIH, Metabolic Neuroprotection: Creative Supplementation in Human Brain, 2 years, $518,936
  • Nancy Ruddle, NIH, Lymphotoxin and Lymphoid Neogenesis, 1 year, $82,437
  • Albert Sinusas, NIH, Hybrid Imaging of Angiogenesis and Arteriogenesis, 4 years, $1,652,083
  • Anthony Van den Pol, NIH, Cytomegalovirus in the Brain, 5 years, $2,043,750
  • Detlef Wencker, NIH, Studies of Myocyte Apoptosis in Congestive Heart Failure, 5 years, $790,862
  • Sandra Wolin, NIH, Biogenesis of Small RNAs, 4 years, $1,346,148
  • Tongzhang Zheng, NIH, Environment, Gene and Testicular Cancer Risk, 5 years, $5,079,796

  • Elizabeth Claus, Susan G. Komen Breast Cancer Foundation, Ductal Carcinoma in situ and BRCA1/2: Outcomes and Risk Prediction, 2 years, $249,823
  • Robert Constable, Pfizer, Inc., MR Methodologies and Further Analysis and Reporting of Data, 2 months, $25,181
  • Gail D’Onofrio, Yale-New Haven Health System, Disaster Preparedness and Emergency Response Education and Research, 1 year, $55,000
  • Deepak D’Souza, Astra Zeneca, L.P., Nicotinic Modulation of a Noncompetitive NMethyl-d-Aspartate (NMDA) Receptor Antagonist–Induced Schizophrenia-Like Information Processing Deficits in Humans, 1 year, $496,454
  • Daniel Goldstein, Roche Organ Transplantation Foundation, Role of Innate B1 Lymphocytes in Neonatal Transplant Tolerance, 2 years, $162,920
  • Zhiwei Hu, Susan G. Komen Breast Cancer Foundation, Targeting the Neovasculature for Immunotherapy and Photodynamic Therapy of Breast Cancer, 2 years, $250,000
  • Sven-Eric Jordt, Health Effects Institute, Health Effects of Air Pollution, 1 year, $80,000
  • Amy Justice, University of Kentucky, Computer Alcohol Interventions for HIV+ Veterans, 1 year, $29,219
  • Arie Kaffman, American Psychiatric Institute for Research and Education, The Effects of Postnatal Maternal Care on Neurogenesis During Development and Their Implications for the Development of Vulnerability to Stress, 1 year, $45,000
  • John Krystal, National Alliance for Research on Schizophrenia and Depression, GABRA2 Modulation of NMDA Receptor Deficit–Related PFC Dysfunction, 1 year, $100,000
  • Elias Lolis, University of Florida, Viral-Based Chemokine Receptor Antagonist, 1 year, $85,515; Avigen, Inc., Stage 1: Preliminary Characterization of a MIF Inhibitor, 1 year, $25,501
  • Paul Lombroso, National Alliance for Research on Schizophrenia and Depression, Characterization of the Step Knock-Out Mouse, 1 year, $99,360
  • Diane McMahon-Pratt, University of Iowa, Collaborative Development of a Vaccine Against Cutaneous and Visceral Leishmanias, 5 years, $156,176
  • Guillermo Mor, Novogen Limited, Assay of Induction Apoptosis by Phenoxodiol in Cancer Cells, 1 year, $89,920
  • Prakash Nadkarni, Mount Sinai School of Medicine, WTC Medical Monitoring Program Data and Preventive Medicine, 3 years, $506,698
  • Angus Nairn, National Alliance for Research on Schizophrenia and Depression, Neuroproteomic Analysis of the Actions of BDNF and Other Neurotrophic Factors, 1 year, $99,900
  • Jill Reiter, Susan G. Komen Breast Cancer Foundation, Prognostic Significance of Soluble EGFR Expression in Breast Cancer, 2 years, $250,000
  • Sara Rockwell, PharmaMar USA, Inc., Preliminary Studies of the Effects of Aplidine in Hypoxic Environments and in Combination with Radiation, 1 year, $67,035